Cargando…
Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea
BACKGROUND: One of the most prescribed treatments for benign prostatic hyperplasia (BPH) is 5α-reductase inhibitors (5ARI). Europe experienced recent safety issues involving 5ARI and depression symptoms, with similar findings being seen in Western countries. The South Korea has updated the drug labe...
Autores principales: | Yeon, Bora, Suh, Ah Young, Choi, Eunmi, Kim, Bonggi, Noh, Eunsun, Chung, Soo Youn, Han, Soon Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926175/ https://www.ncbi.nlm.nih.gov/pubmed/35294468 http://dx.doi.org/10.1371/journal.pone.0265169 |
Ejemplares similares
-
Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case–control study
por: Son, Nayeong, et al.
Publicado: (2022) -
Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea
por: An, Min Ho, et al.
Publicado: (2023) -
Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
por: Yang, Hyeri, et al.
Publicado: (2022) -
α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012) -
Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)